Vimarsana
Biggest News Aggregation in the World

Page 27 - Improving Lives News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Improving Lives. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Improving Lives Today - Breaking & Trending Today

Transcorp Half-Year Performance Shows Powerful Growth as Profit Leaps by 713% - Vimarsana News

Transcorp Half-Year Performance Shows Powerful Growth as Profit Leaps by 713%

Transcorp Half-Year Performance Shows Powerful Growth as Profit Leaps by 713% Posted by African ExaminerAfrican News, Business News, Latest News Friday, July 30th, 2021 (AFRICAN EXAMINER) – Transnational Corporation of Nigeria Plc (Transcorp) has released its unaudited results for the half-year ended June 2021, recording significant improvement across its major income lines. The Conglomerate with strategic investments in the Power, Hospitality, and Energy sectors, recorded a profit after tax of N6.5bn, rising by 713% up from N0.8bn recorded in June of the previous year. Other key ...

KPS Capital Partners To Acquire Controlling Stake In Tate & Lyle's Primary Products Business In North America And Latin America - Vimarsana News

KPS Capital Partners To Acquire Controlling Stake In Tate & Lyle's Primary Products Business In North America And Latin America

KPS Capital Partners To Acquire Controlling Stake In Tate & Lyle's Primary Products Business In North America And Latin America New Company Will Be A Leading Manufacturer Of Plant-Based Products For The Food And Industrial Markets Company To Focus On Growth And Sustainability Tate & Lyle PLC To Retain Approximately 50% Ownership Interest News provided by Share this article Share this article NEW YORK, July 12, 2021 /PRNewswire/ -- KPS Capital Partners, LP ("KPS") announced today that it has entered into a definitive purchase agreement with Tate & Lyle PLC ("Tate & Lyle") (LSE: TATE.L) to ac...

The Future of UK Clinical Research Delivery: 2021 to 2022 implementation plan - Vimarsana News

The Future of UK Clinical Research Delivery: 2021 to 2022 implementation plan

The Future of UK Clinical Research Delivery: 2021 to 2022 implementation plan Request an accessible format. If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@dhsc.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use. Details In March 2021, the government published Saving and Improving Lives: The Future of UK Clinical Research Delivery. This set out our vision to unleash the full potential of UK clinical research delivery to hel...

Source: gov.uk
£64 million funding to back UK-wide plan to strengthen clinical research delivery - Vimarsana News

£64 million funding to back UK-wide plan to strengthen clinical research delivery

Better health outcomes through more effective and efficient research as seen throughout the pandemic Promoting a patient-centred, innovative and data-enabled clinical research environment Embedding research in the NHS to increase UK’s capacity and capability to deliver cutting-edge clinical research Patients across the UK will benefit from a super-charged clinical research system, backed by over £64 million of dedicated investment, which will save lives across the country. The activity for the coming months will include: the development and trial of new COVID-19 treatments and vaccines mak...

Invivoscribe Premieres 12-Color Flow Cytometry Capabilities at their Reference Labs in the US, Europe, and China - Vimarsana News

Invivoscribe Premieres 12-Color Flow Cytometry Capabilities at their Reference Labs in the US, Europe, and China

(0) Today Invivoscribe, a global leader in precision diagnostics, announced the launch of a new 12-color multiparametric flow cytometry service in Shanghai, China, the newest reference laboratory in their international LabPMM network. Flow cytometry has long been the standard of care for many blood cancers including acute myeloid leukemia (AML), but to achieve minimal residual disease (MRD) level sensitivity with limited specimen, powerful 12-color multiparametric flow cytometry (MFC) is needed. By providing the combination of 12-color flow cytometry and next-generation sequencing (NGS) MRD c...